期刊文献+

瑞格列奈联合罗格列酮对糖尿病患者的降糖效果分析

Hypoglycemic effect analysis of repaglinide joint rosiglitazone in the treatment of patients with diabetes
下载PDF
导出
摘要 目的:分析瑞格列奈联合罗格列酮治疗糖尿病患者的临床疗效,着重探讨其降糖效果。方法:2014年1月-2014年10月收治2型糖尿病患者90例,随机分为对照组和观察组,各45例。对照组单纯给予罗格列酮,2 mg/次,2次/d口服治疗。观察组则在此基础上联合给予瑞格列奈起始0.5 mg/次,餐前15 min口服,3次/d,后期根据患者的血糖情况进行适当调整,可增加至2 mg/次,2周为1个疗程,连续治疗8个疗程。治疗后观察两组患者血糖值的变化情况,计算临床治疗的有效率。结果:对照组有效率73.3%,观察组有效率93.3%,观察组的有效率明显高于对照组,两组有效率比较差异有统计学意义(P<0.05)。两组患者治疗后血糖值均降低,观察组降糖效果更加显著,可更好地降低患者血糖值,两组比较差异具有统计学意义(P<0.05)。结论:瑞格列奈联合罗格列酮能产生一定的协同作用,有效降低血糖,疗效显著,安全性良好,值得临床应用推广。 Objective:To analyze the clinical curative effect of repaglinide joint rosiglitazone in the treatment of patients with diabetes and discusse its hypoglycemic effect.Methods:90 patients with type 2 diabetes from January to October in 2014 were randomly divided into the control group and the observation group,with 45 cases in each group.The control group were simply given rosiglitazone,2 mg/time,2 times/d.The observation group were given repaglinide starting at 0.5 mg/time,taken orally in 15 minuters before meal,3 times/d,based on the treatment above,and the dose was adjusted appropriate late according to blood glucose in patients,even to 2 mg/time,2 weeks as one period,and consecutive treatment for eight period of treatment.The level changes of blood glucose in both groups after treatment were observed,and the clinical efficient treatment were calculated.Results:The effective rate of the control group was 73.3%,and the effective rate of the observation group was 93.3%.The effective rate of the treatment group was obviously higher than that of the control group,and the difference was statistically significant(P<0.05). The levels of blood glucose were lower after treatment in both groups,and the observation group had more significant hypoglycemic effect,which could reduce the blood glucose in patients, and there was statistically significant difference between the two groups(P<0.05).Conclusion:Repaglinide joint rosiglitazone could produce certain synergy function and reduce the blood glucose effectively,with distinct curative effect and good security,which was worth clinical promotion.
作者 王波
出处 《中国社区医师》 2015年第6期26-27,共2页 Chinese Community Doctors
关键词 瑞格列奈 罗格列酮 糖尿病 降糖效果 Repaglinide Rosiglitazone Diabetes Hypoglycemic effect
  • 相关文献

参考文献5

二级参考文献28

  • 1马晓静,吴松华,项坤三,陆俊茜,陆蔚,丁虹.精氨酸刺激试验在不同糖代谢状态人群的临床应用[J].中华内分泌代谢杂志,2005,21(3):215-218. 被引量:40
  • 2DISTEFANO JK, WATANABE RM. Pharmacogenetics of anti- diabetes drugs [J]. Pharmaceuticals (Basel), 2010, 3 (8): 2610-2646.
  • 3GRANT SF, THORLEIFSSON G, REYNISDOTTIR I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes[J]. Nat Genet, 2006, 38(3): 320-323.
  • 4NELSON WJ, NUSSE R. Convergence of Wnt, beta-catenin, and cadherin pathways[J]. Science, 2004, 303 (5663) : 1483 - 1487.
  • 5CHANG YC, CHANG TJ, JIANG YD, et al. Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population[J]. Diabetes, 2007, 56(10): 2631-2637.
  • 6DORNHORST A. Insulinotropic meglitinide analogues [J]. Lancet, 2001, 358(9294): 1709-1716.
  • 7YU M, XU XJ, YIN JY, et al. KCNJll Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes[J]. Clin Pharmacol Ther, 2010, 87(3): 330-335.
  • 8ALIBEGOVIC AC, SONNE MP, HφJBJERRE L, et al. The T- allele of TCF7L2 rs7903146 associates with a reduced compensation of insulin secretion for insulin resistance induced by 9 days of bed rest[J]. Diabetes, 2010, 59(4) : 836-843.
  • 9WEN J, RONN T, OLSSEN A, et al. Investigation of type 2 diabetes risk alleles support CDKN2A/B, CDKAL1, and TCF7L2 as susceptibility genes in a Han Chinese cohort[J]. PLoS One, 2010, 5(2): e9153.
  • 10TAN MH. How pioglitazone affects glucose and lipid metabolism [J]. Exp Clin Endocrinol Diabetes, 2000, 108 Suppl 2: S224- S233.

共引文献6772

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部